Search results
Results from the WOW.Com Content Network
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [16] Lisdexamfetamine is taken by mouth. Its effects generally begin within two hours ...
More than 6 million children in the U.S. have been diagnosed with ADHD, one of the most common neurodevelopmental disorders, according to the Centers for Disease Control and Prevention.Millions of ...
The number of new psychiatric drugs, and especially antidepressants on the market in Japan, is significantly less than Western countries. [1]One of the biggest barriers to antidepressants coming to the market is that the medical insurance system in Japan is national, and the authorities are keen to contain a potentially explosive market for drugs like antidepressants that, from the Japanese ...
Data released by the U.S. Centers for Disease Control and Prevention in May showed that 1 million more kids and adolescents in the U.S. received an ADHD diagnosis — 7.1 million kids total — in ...
The FDA approved generic versions of Vyvanse from 11 drugmakers, including U.S.-based drugmakers Mallinckrodt and Viatris, UK-based Hikma Pharmaceuticals, and Indian drugmaker Sun Pharmaceutical ...
Date — — — — — — — 2020/04/01 5 1 4 1 2 3 18 14 66 19 4 1 1 3 1 3 2 5 2 1 5 1 4 7 34 14 1 3 32 1 3 1 1 4 [i 25]: 2020/04/01 267: 2500: 3 69: 505
Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo; Viibryd – an antidepressant of the serotonin modulator and stimulators class; Vivactil (protriptyline) an antidepressant also used in the treatment of nerve pain
Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019. Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions.